Rubicon Research Limited

Rubicon Research Ltd share price declined by 0.25% to Rs 1617.95. The Company's net profit expanded by 10.41% to Rs 84.78 crore, while revenue from operations slightly gained 3.97% to Rs 534.34 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.4 lakh crore, gaining 4.13%. It has improved by 0.06% over last one week and rose by 9.58% in last one month while the market capitalization of Rubicon Research Ltd has inched up 1.39% and 65.14% in the same period respectively. Profit before tax (PBT) of Rubicon Research Ltd stood at Rs 110.37 crore in Q2 FY26, jumping 85.31% year-on-year, and rising by 11.84% quarter-on-quarter. EBITDA came in at Rs 123 crore, surging by 57.29% YoY and easing 6.32% sequentially. Total expenses posted a minor rise of 3.16% to Rs 420.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 153.93 crore, marginally falling by 0.81% YoY, while employee benefits expense was at Rs 85.67 crore, witnessing a strong rise of 25.34% YoY. For the TTM ended FY26, revenue from operations surged 36.57% to Rs 1753.96 crore, while net profit saw a strong growth of 83.64% to Rs 246.74 crore, compared to previous TTM. EBITDA soared by 26830% to Rs 392.51 crore, and PBT witnessed a strong rise of 64.78% to Rs 320.53 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 205.05 crore in FY26, as against Rs 159.18 crore in FY25. Rubicon Research Ltd surged by 157.86% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.21% during the same period.

Rubicon Research Ltd share price slipped 2.03% to Rs 1622.0. The Company's net profit expanded by 10.41% to Rs 84.78 crore, while revenue from operations slightly gained 3.97% to Rs 534.34 crore in Q2FY26 over Q1FY26. The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 25.19 lakh crore, gaining 4.63%. It has inched up 0.66% over last one week and rose by 11.20% in last one month while the market capitalization of Rubicon Research Ltd has marginally improved by 4.29% and 69.31% in the same period respectively. Profit before tax (PBT) of Rubicon Research Ltd stood at Rs 110.37 crore in Q2 FY26, jumping 85.31% year-on-year, and heading higher 11.84% quarter-on-quarter. EBITDA came in at Rs 123 crore, surging by 57.29% YoY and easing 6.32% sequentially. Total expenses posted a minor rise of 3.16% to Rs 420.36 crore in Q2FY26 over Q2FY25. During the quarter, cost of materials consumed stood at Rs 153.93 crore, marginally falling by 0.81% YoY, while employee benefits expense was at Rs 85.67 crore, soaring 25.34% YoY. For the TTM ended FY26, revenue from operations jumped by 36.57% to Rs 1753.96 crore, while net profit surged by 83.64% to Rs 246.74 crore, compared to previous TTM. EBITDA witnessed a strong improvement of 26830% to Rs 392.51 crore, and PBT jumped 64.78% to Rs 320.53 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 205.05 crore in FY26, as against Rs 159.18 crore in FY25. Rubicon Research Ltd rallied 158.51% in last one year, significantly outperforming the benchmark BSE Sensex which has softened by 3.05% during the same period.

Rubicon Research Limited announced the appointment of Mr. Rohit Saraogi as Chief Financial Officer, effective August 14, 2026, while current CFO Mr. Nitin Jajodia will transition to a Chief Commercial Officer role. Additionally, the company’s board re-appointed Mr. Venkat Changavalli as Chairman, extending his term from September 18, 2026, to June 10, 2027.

Rubicon Research Limited, formerly known as Rubicon Research Private Limited, will hold a board meeting on August 14, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Limited. The trading window for the company's shares has been closed since July 1, 2026, and will remain closed until 48 hours after the announcement of the financial results.

Rubicon’s latest sustainability report highlights efforts toward social and environmental responsibility, though it lacks detailed quantitative data and demonstrates a compliance-focused approach. The report, which addresses principles ranging from stakeholder engagement to product safety, details mechanisms like the “Sankalp” group for community outreach and a formal grievance redressal process. While the company provides Patient Information Leaflets and emphasizes pharmacovigilance, the report omits specifics on environmental footprint reduction, labor practices beyond wage percentages (ranging from 0% in rural areas to 50.30% in metropolitan areas), and data privacy frameworks. Notably, several key principles, including fair lending practices and vocational training, are not addressed, and the company reports zero consumer complaints. The report indicates 5% of products were directly sourced from MSMEs/small producers in 2025-26, up from 2% the previous year, with 45% sourced within India.

Rubicon Research announced that the 27th Annual General Meeting(AGM) of the company will be held on 26 August 2026.

The board of Rubicon Research at its meeting held on 20 July 2026 has approved the scheme of merger of for Kia Health Tech, a wholly owned subsidiary, (Transferor Company) with the company.

Rubicon Research has fixed 07 August 2026 as record date for payment of final dividend for FY 2026.

Rubicon Research has allotted 1,49,158 equity shares under ESOS on 20 July 2026. Consequently, the issued, subscribed and paid-up equity share capital of the Company stands increased to Rs 16,55,31,908 comprising of 16,55,31,908 equity shares of face value Re 1 each.

The inspection was carried out from 29 June to 3 July 2026 and marked the first US FDA review of the facility since its acquisition by the company last year. Rubicon Research said that during the 12 months following the acquisition, it completed the integration of the facility, implemented its quality management systems, and fulfilled regulatory filing requirements that led to the inspection. At the conclusion of the inspection, the US FDA issued a Form 483 with two observations. The company clarified that the observations are procedural in nature and do not relate to data integrity. It added that it is confident of working closely with the regulator to address the observations and complete the evaluation process in a timely manner. Rubicon Research said a successful outcome of the inspection, achieved a little over a year after acquiring the facility, would reflect its strong quality and compliance culture and reinforce its regulatory track record. The company also reiterated its earlier guidance and stated that it remains confident of ramping up commercial operations at the facility from the first quarter of calendar year 2027. Rubicon Research is a pharmaceutical formulations company focused on innovation-led research and development, with a growing portfolio of specialty products and drug'device combination offerings aimed at regulated markets. Rubicon Research surged 12.55% to Rs 1,130 after the company's consolidated net profit soared 100% to Rs 76.78 crore on a 43.49% increase in revenue from operations to Rs 513.91 crore in Q4 FY26 over Q4 FY25. The counter jumped 4.69% to Rs 1,363.80 on the BSE. Powered by Capital Market - Live